摘要成纤维细胞活化蛋白(FAP)是一种Ⅱ型膜结合糖蛋白,其在90％的上皮肿瘤、伤口愈合或炎症部位的成纤维细胞中过表达,而在正常组织中低表达或不表达,是疾病诊疗的重要靶点之一.68Ga-FAPI-04是基于喹啉类FAP抑制剂开发的PET诊断药物,在患者体内外均表现出对FAP的高度特异性与亲和力,在基础研究及临床应用中均得到广泛关注.笔者就68Ga-FAPI-04的基本概况及其在多种恶性肿瘤、非肿瘤疾病中的应用进展进行综述.

abstractsFibroblast activation protein(FAP)is a type Ⅱ membrane-bound glycoprotein that is overexpressed in fibroblasts of 90％epithelial tumors,wound healing or inflammatory sites,but is low or absent in normal tissues,and is an important target for disease diagnosis and treatment.68Ga-FAPI-04 is a PET diagnostic drug based on quinoline-based FAP inhibitors,which has shown high specificity and affinity for FAP in patients both in vivo and in vitro,and has received wide attention in basic research and clinical applications.The author reviewed the basic overview of 68Ga-FAPI-04 and its application in various malignant and non-cancerous diseases.